Abstract
The blood brain barrier (BBB) maintains homeostasis by regulating the transport of chemicals at the brain interface. However, it is also one of the largest obstacles for drug delivery to the central nervous system (CNS). The utilization of nanoparticles as drug delivery vehicles is one potential solution to overcome this barrier. This review highlights the characteristics of the BBB that inhibit the passage of drugs to the brain, evaluates the efficiency of current in vitro models to mimic the BBB, and discusses the use of nanoparticles in both in vivo and in vitro models to enhance drug permeability across the barrier. In addition, this review describes factors that influence the passage of nanoparticles (type of polymers and surfactant coating, nanoparticle size) across the barrier. Protein opsonization and phagocytic activity of the reticuloendothelial system limits the amount of drug delivered to the brain, and this article summarizes methods to circumvent these issues. This paper also reviews literature covering opportunities and challenges provided with current applications of nanoparticle drug delivery systems for diseases of the brain, including cancer, HIV, and Alzheimer’s disease.
Keywords: Nanoparticles, Blood Brain Barrier, polysorbate 80, TEER, Endothelial Cells.
Current Pharmaceutical Biotechnology
Title:Nanoparticle Enabled Drug Delivery Across the Blood Brain Barrier: in vivo and in vitro Models, Opportunities and Challenges
Volume: 14 Issue: 14
Author(s): Meeta Gidwani and Ajay V. Singh
Affiliation:
Keywords: Nanoparticles, Blood Brain Barrier, polysorbate 80, TEER, Endothelial Cells.
Abstract: The blood brain barrier (BBB) maintains homeostasis by regulating the transport of chemicals at the brain interface. However, it is also one of the largest obstacles for drug delivery to the central nervous system (CNS). The utilization of nanoparticles as drug delivery vehicles is one potential solution to overcome this barrier. This review highlights the characteristics of the BBB that inhibit the passage of drugs to the brain, evaluates the efficiency of current in vitro models to mimic the BBB, and discusses the use of nanoparticles in both in vivo and in vitro models to enhance drug permeability across the barrier. In addition, this review describes factors that influence the passage of nanoparticles (type of polymers and surfactant coating, nanoparticle size) across the barrier. Protein opsonization and phagocytic activity of the reticuloendothelial system limits the amount of drug delivered to the brain, and this article summarizes methods to circumvent these issues. This paper also reviews literature covering opportunities and challenges provided with current applications of nanoparticle drug delivery systems for diseases of the brain, including cancer, HIV, and Alzheimer’s disease.
Export Options
About this article
Cite this article as:
Gidwani Meeta and Singh V. Ajay, Nanoparticle Enabled Drug Delivery Across the Blood Brain Barrier: in vivo and in vitro Models, Opportunities and Challenges, Current Pharmaceutical Biotechnology 2013; 14 (14) . https://dx.doi.org/10.2174/1389201015666140508122558
DOI https://dx.doi.org/10.2174/1389201015666140508122558 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry Translocator Protein Ligands as Promising Therapeutic Tools for Anxiety Disorders
Current Medicinal Chemistry Physiology, Pharmacology and Pathophysiology of the pH Regulatory Transport Proteins NHE1 and NBCn1: Similarities, Differences, and Implications for Cancer Therapy
Current Pharmaceutical Design Meet the Editorial Board:
Current Alzheimer Research Carbohydrates: Potential Sweet Tools Against Cancer
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Medicinal Chemistry LAT1 Targeted Delivery of Methionine Based Imaging Probe Derived from M(III) Metal Ions for Early Diagnosis of Proliferating Tumours using Molecular Imaging Modalities
Current Cancer Drug Targets Apoptosis Signaling Pathways in Anticancer Therapy
Current Cancer Therapy Reviews Interaction and Structural Modification of Topoisomerase IIα by Peptidyl Prolyl Isomerase, pin1: An In Silico Study
Protein & Peptide Letters Microdialysis as an Excellent Sampling Approach for Biomedical Analysis
Current Pharmaceutical Analysis Emerging Facts on Chronic Consumption of Aspartame as Food Additive
Current Nutrition & Food Science Epidermal Growth Factor Receptor as a Target for Anti-Cancer Agent Design
Anti-Cancer Agents in Medicinal Chemistry Noscapine and its Analogs as Chemotherapeutic Agent: Current updates
Current Topics in Medicinal Chemistry Activatable Optical Probes for the Detection of Enzymes
Current Organic Synthesis Copper Chelation Chemistry and its Role in Copper Radiopharmaceuticals
Current Pharmaceutical Design Tracking Stem Cells for Cellular Therapy in Stroke
Current Pharmaceutical Design Matrix Metalloproteinase Inhibitor MMI-166 Suppresses the Growth of SW1990 Human Pancreatic Cancer Cells
Current Signal Transduction Therapy Serotonin and Cancer: What Is the Link?
Current Molecular Medicine The Gene Expression Profiles of Medulloblastoma Cell Lines Resistant to Preactivated Cyclophosphamide
Current Cancer Drug Targets Personalizing Stem Cell Research and Therapy: The Arduous Road Ahead or Missed Opportunity?
Current Pharmacogenomics and Personalized Medicine